Physician profile
Michele E Horne
NPI 1972839363
$2,825.22
in general payments reported to CMS, 2019-2025
15 companies · $352 in 2025
The $352 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.14 · 2020: $40.12 · 2021: $589 · 2022: $628 · 2023: $765 · 2024: $423 · 2025: $352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,540.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,540.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $756.05 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $660.53 | 2021-2025 | |
| Lilly USA, LLC | $451.44 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $226.16 | 2023-2025 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $212.95 | 2021 | |
| Pfizer INC. | $145.46 | 2023-2024 | |
| Neurocrine Biosciences, INC. | $86.52 | 2022 | |
| Exact Sciences Corporation | $77.39 | 2023-2024 | Cologuard Collection Kit |
| Allergan, INC. | $54.27 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $36.17 | 2021 | |
| Averitas Pharma INC. | $31.19 | 2023 | Qutenza |
| Alnylam Pharmaceuticals INC. | $26.49 | 2023 | Onpattro |
| Lundbeck LLC | $25.84 | 2023 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $20.77 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Horne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.